Fennec Pharmaceuticals Inc. operates as a commercial stage biopharmaceutical company in the United States. The company’s product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of cisplatin-induced ototoxicity pediatric patients. It sells its products through regional pediatric oncology specialists and medical science liaisons. Fennec Pharmaceuticals Inc. has collaboration with Tampa General Hospital Foundation, Inc. for evaluation of clinical utility of sodium thiosulfate injection in reducing the risk of ototoxicity in adolescent, young adult, and adult cancer patients receiving cisplatin-based treatment; and Norgine Pharma UK Limited. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina.
| Business Activity | PASS |
| Debt Ratio (0.00%) | PASS |
| Cash Ratio (0.11%) | PASS |
| Receivables Ratio (0.00%) | PASS |
| Revenue Ratio (0.00%) | PASS |
| Overall | PASS |
| Date | EPS Est. | Reported EPS | Surprise % |
|---|---|---|---|
| 2026-08-13 | 0.02 | Pending | — |
| 2026-05-14 | -0.02 | 0.01 | +160.0% |
| 2026-03-24 | 0.04 | -0.10 | -350.2% |
| 2025-11-13 | -0.02 | -0.02 | +20.0% |
| 2025-08-14 | -0.03 | -0.11 | -281.7% |
| 2025-05-13 | -0.08 | -0.04 | +52.9% |
| 2025-03-10 | -0.13 | -0.06 | +53.9% |
| 2024-11-07 | -0.08 | -0.21 | -162.5% |
| Period | Revenue | Net Income | EBITDA | Gross Profit | Op. Income | EPS |
|---|---|---|---|---|---|---|
| 2026-03-31 | $15.1M | $201.0K | $234.0K | $14.5M | -$119.0K | 0.01 |
| 2025-12-31 | $13.8M | -$4.8M | -$4.3M | $12.0M | -$2.6M | -0.17 |
| 2025-09-30 | $12.5M | -$638.0K | -$26.0K | $11.8M | -$201.0K | -0.02 |
| 2025-06-30 | $9.7M | -$3.2M | -$2.5M | $8.7M | -$2.7M | -0.11 |
| 2025-03-31 | $8.8M | -$1.2M | -$547.0K | $8.4M | -$821.0K | -0.04 |
| 2024-12-31 | — | — | — | — | — | — |
| Date | Name | Role | Shares | Value |
|---|---|---|---|---|
| 2026-05-11 | RALLIS CHRISTOPHER ANIGERON | Director | 14,344 | $35.0K |
| 2026-05-11 | RALLIS CHRISTOPHER ANIGERON | Director | 8,346 | $58.8K |
| 2026-05-01 | RAYKOV ROSTISLAV CHRISTOV | Director | 18,376 | $38.2K |
| 2026-05-01 | RAYKOV ROSTISLAV CHRISTOV | Director | 10,781 | $69.8K |
| 2026-04-30 | CIOFFI CHRISTIANA MARIE | Officer | 155 | — |
| 2026-04-30 | EVANS TERRY L | Officer | 168 | — |
| 2026-04-30 | HACKMAN JEFFREY S | Chief Executive Officer | 1,159 | — |
| 2026-04-30 | SAYAD PIERRE SARGIS PH.D. | Officer | 168 | — |
| 2026-04-30 | ANDRADE ROBERT C | Chief Financial Officer | 1,703 | — |
| 2026-04-01 | RAYKOV ROSTISLAV CHRISTOV | Director | 15,598 | $38.2K |
| Holder | Shares | Value | % Held |
|---|---|---|---|
| Rosalind Advisors, Inc. | 2.9M | $28.9M | 0.1% |
| Southpoint Capital Advisors Lp | 2.7M | $27.3M | 0.1% |
| Solas Capital Management, LLC | 2.5M | $24.6M | 0.1% |
| AIGH Capital Management LLC | 2.0M | $19.7M | 0.1% |
| Blackrock Inc. | 1.4M | $13.6M | 0.0% |
| Vanguard Capital Management LLC | 897.1K | $8.9M | 0.0% |
| AWM Investment Company, Inc. | 720.1K | $7.2M | 0.0% |
| Geode Capital Management, LLC | 371.7K | $3.7M | 0.0% |
| State Street Corporation | 359.1K | $3.6M | 0.0% |
| Potomac Capital Management, Inc. | 224.4K | $2.2M | 0.0% |
Buy
Hold
Sell
Strong Sell
$304.8M
9.10
0.913
6
$51.0M
1.29
7.12
0.0%
35
| Date | Estimate | Reported | Surprise |
|---|---|---|---|
| 2026-08-13 | $0.02 | Pending | — |
| 2026-05-14 | $-0.02 | $0.01 | +160.0% |
| 2026-03-24 | $0.04 | $-0.10 | -350.2% |
| 2025-11-13 | $-0.02 | $-0.02 | +20.0% |
| 2025-08-14 | $-0.03 | $-0.11 | -281.7% |
| 2025-05-13 | $-0.08 | $-0.04 | +52.9% |
| Shares | Cost | Profit to Target | R:R |
|---|---|---|---|
| To Consensus ($15.57, 7 analysts) | |||
| 10 | $97.90 | +$57.80 (59%) | 3.9R |
| 50 | $489.50 | +$289.00 (59%) | 3.9R |
| 100 | $979.00 | +$578.00 (59%) | 3.9R |
| To Fair Value ($31.15) | |||
| 10 | $97.90 | +$213.60 (218%) | 14.5R |
| 50 | $489.50 | +$1,068.00 (218%) | 14.5R |
| 100 | $979.00 | +$2,136.00 (218%) | 14.5R |
- Elevated short interest (7.12 days to cover)
A single score combining all analytical layers below. A is strongest, D is weakest.
How much could this ticker lose on a bad day? These metrics measure worst-case scenarios from historical data.
Based on 10,000 simulated price paths, here is the probability of where this ticker could be in 30, 60, and 90 days.
What direction is this ticker actually moving, filtered through noise? Is it speeding up or slowing down?
Classic chart signals that institutional traders monitor. Golden Cross is bullish, Death Cross is bearish.
Is this company financially sound? The Z-Score measures bankruptcy risk. The F-Score measures fundamental strength.
These tickers tend to move together (positive) or in opposite directions (negative). Useful for portfolio diversification.
| Ticker | Correlation |
|---|---|
| IWM | 0.381 |
| ARKG | 0.375 |
| CLDX | 0.364 |
| DNLI | 0.346 |
| IDYA | 0.345 |
| Ticker | Correlation |
|---|---|
| LIANY | -0.249 |
| TIJARA.KW | -0.232 |
| NBRVF | -0.178 |
| LEJUY | -0.166 |
| 7912.T | -0.154 |
Does this ticker have consistent patterns on certain days or months? Historical tendencies, not guarantees.
After this company beats earnings, does the price keep going up? Drift tracks post-earnings momentum.
How does this ticker’s recent performance compare to the entire universe? Ranked across 1, 3, 6, and 12-month returns.
Related Tickers
Similar in Healthcare
Also in TE500